[FWP] Inverse VIX Short-Term Futures ETNs due March 22, 2045 Free Writing Prospectus
Walgreens Boots Alliance, Inc. (WBA) filed a Form 8-K to voluntarily supplement the definitive proxy statement for its pending merger with affiliates of Sycamore Partners (“Blazing Star Parent”). The supplements respond to two shareholder lawsuits (Drulias v. Babiak, Johnson v. WBA) and 11 demand letters that claim material omissions in the original proxy. Although WBA believes the claims are meritless, the company is adding detailed narrative and quantitative information to moot disclosure challenges and avoid possible injunctions ahead of the July 11, 2025 special shareholder meeting.
Key additions include: (1) expanded background on negotiations with Sycamore, confidentiality terms and board deliberations; (2) fuller descriptions of Centerview’s and Morgan Stanley’s relationship-disclosure memoranda; (3) granular valuation work-ups—public-company comparables, precedent transactions, discounted cash-flow (DCF) and premiums-paid analyses—with explicit multiples, discount rates and liability adjustments; and (4) refreshed prospective financial information (February Projections, VMD Forecasts, prior projection iterations).
Valuation highlights: Centerview’s selected-public-company approach implies equity value of $4.60–$12.70 per share, precedent-transaction analysis $6.90–$15.20, and DCF $10.80–$19.10. Morgan Stanley’s CY2025E P/E comparables yield $7.95–$12.25, while its premiums-paid screen suggests an implied price of $10.60–$12.80. These ranges bracket the merger consideration of $12.64–$13.36 disclosed in the proxy.
Lawsuit status: Plaintiffs seek to halt the vote until additional information is provided and request attorneys’ fees. WBA discloses that further suits or demand letters may arrive but will not necessarily be reported absent new allegations.
Financial outlook (February Projections): FY2025 revenue $154.6 bn, Adjusted EBITDA $3.71 bn, Unlevered FCF $1.99 bn. Adjusted EBITDA is projected to grow to $4.70 bn by FY2029. Key drags include opioid payments, dark-rent obligations and store-closure costs.
Strategic context: The board continues to recommend the Sycamore transaction and notes limited interest from alternative sponsors or strategics. A “go-shop” remains part of the agreed deal structure. WBA reiterates it is not admitting materiality of the new disclosures.
Walgreens Boots Alliance, Inc. (WBA) ha presentato un Modulo 8-K per integrare volontariamente la dichiarazione definitiva di procura relativa alla sua fusione in corso con affiliate di Sycamore Partners (“Blazing Star Parent”). Le integrazioni rispondono a due cause legali da parte di azionisti (Drulias v. Babiak, Johnson v. WBA) e 11 lettere di richiesta che denunciano omissioni materiali nella proxy originale. Sebbene WBA ritenga infondate tali accuse, la società sta aggiungendo informazioni narrative e quantitative dettagliate per superare le contestazioni sulle divulgazioni ed evitare possibili ingiunzioni prima dell’assemblea speciale degli azionisti del 11 luglio 2025.
Principali integrazioni includono: (1) ampliamento del contesto sulle trattative con Sycamore, termini di riservatezza e deliberazioni del consiglio; (2) descrizioni più complete dei memorandum di divulgazione delle relazioni di Centerview e Morgan Stanley; (3) analisi di valutazione dettagliate—confronti con società quotate, transazioni precedenti, flussi di cassa scontati (DCF) e analisi dei premi pagati—con multipli espliciti, tassi di sconto e aggiustamenti di responsabilità; e (4) aggiornamento delle informazioni finanziarie prospettiche (Proiezioni di febbraio, previsioni VMD, iterazioni precedenti delle proiezioni).
Punti salienti della valutazione: l’approccio di Centerview basato su società quotate selezionate implica un valore azionario compreso tra $4,60 e $12,70 per azione, l’analisi delle transazioni precedenti tra $6,90 e $15,20, e il DCF tra $10,80 e $19,10. I multipli P/E stimati da Morgan Stanley per il 2025 indicano un valore tra $7,95 e $12,25, mentre la valutazione basata sui premi pagati suggerisce un prezzo implicito tra $10,60 e $12,80. Questi intervalli includono la considerazione della fusione di $12,64–$13,36 indicata nella proxy.
Situazione legale: i querelanti chiedono di sospendere la votazione fino a quando non saranno fornite informazioni aggiuntive e richiedono il pagamento delle spese legali. WBA dichiara che potrebbero arrivare ulteriori cause o lettere di richiesta, ma non saranno necessariamente comunicate in assenza di nuove accuse.
Prospettive finanziarie (Proiezioni di febbraio): ricavi FY2025 $154,6 miliardi, EBITDA rettificato $3,71 miliardi, flusso di cassa libero non indebitato $1,99 miliardi. L’EBITDA rettificato è previsto in crescita fino a $4,70 miliardi entro il FY2029. Le principali voci di costo includono pagamenti per oppioidi, obblighi di affitto oscuri e costi di chiusura negozi.
Contesto strategico: il consiglio continua a raccomandare la transazione con Sycamore e segnala scarso interesse da parte di sponsor alternativi o strategici. È prevista una fase di “go-shop” come parte della struttura dell’accordo. WBA ribadisce di non ammettere la materialità delle nuove divulgazioni.
Walgreens Boots Alliance, Inc. (WBA) presentó un Formulario 8-K para complementar voluntariamente la declaración definitiva de poder relacionada con su fusión pendiente con afiliadas de Sycamore Partners (“Blazing Star Parent”). Los suplementos responden a dos demandas de accionistas (Drulias v. Babiak, Johnson v. WBA) y 11 cartas de demanda que alegan omisiones materiales en el poder original. Aunque WBA considera que las reclamaciones carecen de fundamento, la compañía está añadiendo información narrativa y cuantitativa detallada para zanjar los desafíos de divulgación y evitar posibles medidas cautelares antes de la reunión especial de accionistas del 11 de julio de 2025.
Adiciones clave incluyen: (1) ampliación del contexto sobre las negociaciones con Sycamore, términos de confidencialidad y deliberaciones del consejo; (2) descripciones más completas de los memorandos de divulgación de relaciones de Centerview y Morgan Stanley; (3) análisis de valoración detallados—comparables de empresas públicas, transacciones precedentes, flujo de caja descontado (DCF) y análisis de primas pagadas—con múltiplos explícitos, tasas de descuento y ajustes de pasivos; y (4) actualización de la información financiera prospectiva (Proyecciones de febrero, Pronósticos VMD, iteraciones previas de proyecciones).
Aspectos destacados de la valoración: el enfoque de Centerview basado en empresas públicas seleccionadas implica un valor patrimonial de $4.60 a $12.70 por acción, el análisis de transacciones precedentes de $6.90 a $15.20, y el DCF de $10.80 a $19.10. Los múltiplos P/E estimados por Morgan Stanley para 2025 arrojan un valor de $7.95 a $12.25, mientras que su análisis de primas pagadas sugiere un precio implícito de $10.60 a $12.80. Estos rangos abarcan la consideración de la fusión de $12.64–$13.36 divulgada en el poder.
Estado de las demandas: Los demandantes buscan detener la votación hasta que se proporcione información adicional y solicitan honorarios legales. WBA informa que pueden llegar más demandas o cartas de demanda, pero no necesariamente serán reportadas sin nuevas alegaciones.
Perspectivas financieras (Proyecciones de febrero): ingresos para FY2025 de $154.6 mil millones, EBITDA ajustado de $3.71 mil millones, flujo de caja libre sin apalancamiento de $1.99 mil millones. Se proyecta que el EBITDA ajustado crezca a $4.70 mil millones para FY2029. Los principales factores negativos incluyen pagos por opioides, obligaciones de alquiler oscuro y costos de cierre de tiendas.
Contexto estratégico: El consejo continúa recomendando la transacción con Sycamore y señala un interés limitado de patrocinadores o estratégicos alternativos. Se mantiene una fase de “go-shop” como parte de la estructura del acuerdo. WBA reitera que no admite la materialidad de las nuevas divulgaciones.
Walgreens Boots Alliance, Inc. (WBA)는 Sycamore Partners(“Blazing Star Parent”) 계열사와의 진행 중인 합병에 관한 최종 위임장 설명서를 자발적으로 보완하기 위해 Form 8-K를 제출했습니다. 이번 보완은 두 건의 주주 소송(Drulias v. Babiak, Johnson v. WBA)과 11건의 요구서에 대응한 것으로, 원래 위임장에 중대한 누락이 있다고 주장합니다. WBA는 이러한 주장이 근거 없다고 보지만, 2025년 7월 11일 특별 주주총회 이전에 공개 문제를 해소하고 잠재적 금지명령을 피하기 위해 상세한 서술 및 정량 정보를 추가하고 있습니다.
주요 추가 내용은 다음과 같습니다: (1) Sycamore와의 협상 배경, 비밀 유지 조건 및 이사회 심의 확대; (2) Centerview와 Morgan Stanley의 관계 공개 메모 완전한 설명; (3) 공개 기업 비교, 선례 거래, 할인 현금 흐름(DCF) 및 프리미엄 지급 분석을 포함한 세부 평가 작업—명확한 배수, 할인율 및 부채 조정 포함; (4) 최신 전망 재무 정보(2월 예측, VMD 전망, 이전 예측 버전).
평가 하이라이트: Centerview의 선정된 공개 기업 접근법은 주당 $4.60–$12.70의 자본 가치를 시사하며, 선례 거래 분석은 $6.90–$15.20, DCF는 $10.80–$19.10입니다. Morgan Stanley의 2025년 예상 주가수익비율(P/E) 비교는 $7.95–$12.25를 산출하며, 프리미엄 지급 분석은 $10.60–$12.80의 암시적 가격을 제시합니다. 이 범위들은 위임장에 공개된 합병 대가 $12.64–$13.36를 포함합니다.
소송 현황: 원고들은 추가 정보 제공 전 투표 중단을 요구하며 변호사 비용도 청구하고 있습니다. WBA는 추가 소송이나 요구서가 도착할 수 있으나 새로운 주장 없이는 반드시 보고하지는 않을 것이라고 밝혔습니다.
재무 전망 (2월 예측): 2025 회계연도 매출 $1546억, 조정 EBITDA $37.1억, 무차입 자유현금흐름 $19.9억. 조정 EBITDA는 2029 회계연도까지 $47.0억으로 성장할 것으로 예상됩니다. 주요 부담 요소는 오피오이드 지급, 암대여 의무, 매장 폐쇄 비용입니다.
전략적 맥락: 이사회는 Sycamore 거래를 계속 추천하며 대체 스폰서나 전략적 투자자들의 관심이 제한적임을 언급합니다. "고샵(go-shop)" 조항은 합의된 거래 구조의 일부로 유지됩니다. WBA는 새로운 공개 내용의 중요성을 인정하지 않음을 재확인합니다.
Walgreens Boots Alliance, Inc. (WBA) a déposé un formulaire 8-K pour compléter volontairement la déclaration définitive de procuration concernant sa fusion en cours avec des filiales de Sycamore Partners (« Blazing Star Parent »). Ces compléments répondent à deux poursuites d’actionnaires (Drulias c. Babiak, Johnson c. WBA) et à 11 lettres de demande alléguant des omissions matérielles dans la procuration originale. Bien que WBA considère ces allégations comme infondées, la société ajoute des informations narratives et quantitatives détaillées afin de résoudre les contestations relatives aux divulgations et d’éviter d’éventuelles injonctions avant l’assemblée générale extraordinaire des actionnaires du 11 juillet 2025.
Ajouts clés : (1) contexte élargi sur les négociations avec Sycamore, les termes de confidentialité et les délibérations du conseil d’administration ; (2) descriptions plus complètes des mémorandums de divulgation des relations de Centerview et Morgan Stanley ; (3) analyses d’évaluation détaillées—comparables d’entreprises cotées, transactions antérieures, flux de trésorerie actualisés (DCF) et analyses des primes payées—avec multiples explicites, taux d’actualisation et ajustements de passifs ; (4) informations financières prospectives actualisées (prévisions de février, prévisions VMD, itérations précédentes).
Points forts de l’évaluation : l’approche de Centerview basée sur des entreprises cotées sélectionnées implique une valeur des capitaux propres comprise entre 4,60 $ et 12,70 $ par action, l’analyse des transactions antérieures entre 6,90 $ et 15,20 $, et le DCF entre 10,80 $ et 19,10 $. Les multiples P/E estimés par Morgan Stanley pour 2025 donnent une fourchette de 7,95 $ à 12,25 $, tandis que son analyse des primes payées suggère un prix implicite de 10,60 $ à 12,80 $. Ces fourchettes encadrent la contrepartie de fusion de 12,64 $–13,36 $ divulguée dans la procuration.
Situation des poursuites : Les plaignants demandent de suspendre le vote jusqu’à la fourniture d’informations supplémentaires et réclament les frais d’avocat. WBA indique que d’autres poursuites ou lettres de demande pourraient arriver, mais ne seront pas nécessairement signalées en l’absence de nouvelles allégations.
Perspectives financières (prévisions de février) : chiffre d’affaires pour l’exercice 2025 de 154,6 milliards de $, EBITDA ajusté de 3,71 milliards de $, flux de trésorerie disponible non levier de 1,99 milliard de $. L’EBITDA ajusté devrait atteindre 4,70 milliards de $ d’ici l’exercice 2029. Les principaux freins comprennent les paiements liés aux opioïdes, les obligations de loyers cachés et les coûts de fermeture de magasins.
Contexte stratégique : Le conseil continue de recommander la transaction avec Sycamore et note un intérêt limité de la part d’autres sponsors ou acteurs stratégiques. Une période de « go-shop » reste incluse dans la structure de l’accord. WBA réitère qu’elle ne reconnaît pas la matérialité des nouvelles divulgations.
Walgreens Boots Alliance, Inc. (WBA) hat ein Formular 8-K eingereicht, um freiwillig die endgültige Vollmachtsmitteilung für die bevorstehende Fusion mit Tochtergesellschaften von Sycamore Partners („Blazing Star Parent“) zu ergänzen. Die Ergänzungen reagieren auf zwei Aktionärsklagen (Drulias gegen Babiak, Johnson gegen WBA) und 11 Aufforderungsschreiben, die wesentliche Auslassungen in der ursprünglichen Vollmacht behaupten. Obwohl WBA die Ansprüche für unbegründet hält, fügt das Unternehmen detaillierte narrative und quantitative Informationen hinzu, um Offenlegungsstreitigkeiten auszuräumen und mögliche einstweilige Verfügungen vor der außerordentlichen Hauptversammlung am 11. Juli 2025 zu vermeiden.
Wesentliche Ergänzungen umfassen: (1) erweiterte Hintergrundinformationen zu Verhandlungen mit Sycamore, Vertraulichkeitsbedingungen und Vorstandsdiskussionen; (2) ausführlichere Beschreibungen der Beziehungsoffenlegungsmemoranden von Centerview und Morgan Stanley; (3) detaillierte Bewertungsanalysen—vergleichbare börsennotierte Unternehmen, frühere Transaktionen, Discounted Cash Flow (DCF) und bezahlte Prämien—mit expliziten Multiplikatoren, Diskontierungssätzen und Haftungsanpassungen; sowie (4) aktualisierte vorausschauende Finanzinformationen (Februar-Prognosen, VMD-Forecasts, frühere Prognoseversionen).
Bewertungs-Highlights: Der von Centerview gewählte Ansatz mit vergleichbaren börsennotierten Unternehmen impliziert einen Eigenkapitalwert von $4,60–$12,70 pro Aktie, die Analyse früherer Transaktionen $6,90–$15,20 und der DCF $10,80–$19,10. Die von Morgan Stanley für das Jahr 2025 geschätzten KGV-Vergleiche ergeben $7,95–$12,25, während die Analyse der gezahlten Prämien einen impliziten Preis von $10,60–$12,80 nahelegt. Diese Spannen umfassen die in der Vollmacht angegebenen Fusionsgegenleistungen von $12,64–$13,36.
Rechtslage: Die Kläger verlangen eine Aussetzung der Abstimmung bis zur Bereitstellung zusätzlicher Informationen und fordern Anwaltskosten. WBA gibt an, dass weitere Klagen oder Aufforderungsschreiben eintreffen können, diese jedoch ohne neue Vorwürfe nicht unbedingt gemeldet werden.
Finanzielle Prognose (Februar-Prognosen): Umsatz für das Geschäftsjahr 2025 $154,6 Mrd., bereinigtes EBITDA $3,71 Mrd., unbelasteter Free Cashflow $1,99 Mrd.. Das bereinigte EBITDA soll bis zum Geschäftsjahr 2029 auf $4,70 Mrd. wachsen. Wesentliche Belastungen sind Opioid-Zahlungen, verdeckte Mietverpflichtungen und Kosten für Filialschließungen.
Strategischer Kontext: Der Vorstand empfiehlt weiterhin die Sycamore-Transaktion und weist auf begrenztes Interesse alternativer Sponsoren oder strategischer Investoren hin. Eine „Go-Shop“-Phase bleibt Teil der vereinbarten Struktur. WBA betont, dass keine Anerkennung der Wesentlichkeit der neuen Offenlegungen erfolgt.
- Proactive supplemental disclosures reduce likelihood of court-ordered delays to the July 11, 2025 shareholder vote.
- Comprehensive valuation data equips investors with detailed multiples, discount rates and projections, enhancing transparency.
- Go-shop provision remains in place, preserving the board’s ability to secure superior proposals.
- Two active lawsuits and 11 demand letters create legal uncertainty and potential incremental costs.
- Valuation range peaks at $19.10, implying the offered $12.64–$13.36 could undervalue the company, risking dissent.
- Large quantified liabilities—$3.78 bn opioid exposure and $2.46 bn dark-rent obligations—underscore ongoing cash-flow headwinds.
Insights
TL;DR: Supplemental disclosures aim to de-risk litigation; valuation ranges still straddle offer price, leaving fairness debate alive.
From a deal-making standpoint, WBA’s voluntary amendments are a standard defensive maneuver to neutralize disclosure-based claims that routinely accompany take-private transactions. By front-loading detailed projections, multiples and advisor assumptions, the company reduces the likelihood of an injunction that could delay or derail the July 11 vote. Importantly, the high end of Centerview’s DCF ($19.10) exceeds the $12.64–$13.36 consideration, arming dissenters with an argument that the offer undervalues WBA. However, other methods show values below or in line with the offer, supporting the board’s contention that the deal is fair. The board’s insistence on a go-shop and disclosure of alternative-party outreach also bolster the process defense. Overall impact: neutral to mildly positive for closing probability, modest overhang on pricing fairness.
TL;DR: New information lowers injunction risk but lawsuits persist; liability disclosures highlight sizable opioid and dark-rent burdens.
The filing openly quantifies potential opioid liabilities ($3.78 bn NPV) and dark-rent commitments ($2.46 bn NPV), factors that heavily influence valuation ranges. By incorporating these metrics, WBA strengthens its defense that shareholders are fully informed. While the company expects more suits, precedent shows that robust supplemental disclosures often result in mootness dismissals with relatively minor fee settlements. Nevertheless, the breadth of liabilities and wide valuation dispersion may fuel appraisal-style claims post-merger. On balance, the litigation threat to closing appears low, but the cost and noise are non-trivial.
Walgreens Boots Alliance, Inc. (WBA) ha presentato un Modulo 8-K per integrare volontariamente la dichiarazione definitiva di procura relativa alla sua fusione in corso con affiliate di Sycamore Partners (“Blazing Star Parent”). Le integrazioni rispondono a due cause legali da parte di azionisti (Drulias v. Babiak, Johnson v. WBA) e 11 lettere di richiesta che denunciano omissioni materiali nella proxy originale. Sebbene WBA ritenga infondate tali accuse, la società sta aggiungendo informazioni narrative e quantitative dettagliate per superare le contestazioni sulle divulgazioni ed evitare possibili ingiunzioni prima dell’assemblea speciale degli azionisti del 11 luglio 2025.
Principali integrazioni includono: (1) ampliamento del contesto sulle trattative con Sycamore, termini di riservatezza e deliberazioni del consiglio; (2) descrizioni più complete dei memorandum di divulgazione delle relazioni di Centerview e Morgan Stanley; (3) analisi di valutazione dettagliate—confronti con società quotate, transazioni precedenti, flussi di cassa scontati (DCF) e analisi dei premi pagati—con multipli espliciti, tassi di sconto e aggiustamenti di responsabilità; e (4) aggiornamento delle informazioni finanziarie prospettiche (Proiezioni di febbraio, previsioni VMD, iterazioni precedenti delle proiezioni).
Punti salienti della valutazione: l’approccio di Centerview basato su società quotate selezionate implica un valore azionario compreso tra $4,60 e $12,70 per azione, l’analisi delle transazioni precedenti tra $6,90 e $15,20, e il DCF tra $10,80 e $19,10. I multipli P/E stimati da Morgan Stanley per il 2025 indicano un valore tra $7,95 e $12,25, mentre la valutazione basata sui premi pagati suggerisce un prezzo implicito tra $10,60 e $12,80. Questi intervalli includono la considerazione della fusione di $12,64–$13,36 indicata nella proxy.
Situazione legale: i querelanti chiedono di sospendere la votazione fino a quando non saranno fornite informazioni aggiuntive e richiedono il pagamento delle spese legali. WBA dichiara che potrebbero arrivare ulteriori cause o lettere di richiesta, ma non saranno necessariamente comunicate in assenza di nuove accuse.
Prospettive finanziarie (Proiezioni di febbraio): ricavi FY2025 $154,6 miliardi, EBITDA rettificato $3,71 miliardi, flusso di cassa libero non indebitato $1,99 miliardi. L’EBITDA rettificato è previsto in crescita fino a $4,70 miliardi entro il FY2029. Le principali voci di costo includono pagamenti per oppioidi, obblighi di affitto oscuri e costi di chiusura negozi.
Contesto strategico: il consiglio continua a raccomandare la transazione con Sycamore e segnala scarso interesse da parte di sponsor alternativi o strategici. È prevista una fase di “go-shop” come parte della struttura dell’accordo. WBA ribadisce di non ammettere la materialità delle nuove divulgazioni.
Walgreens Boots Alliance, Inc. (WBA) presentó un Formulario 8-K para complementar voluntariamente la declaración definitiva de poder relacionada con su fusión pendiente con afiliadas de Sycamore Partners (“Blazing Star Parent”). Los suplementos responden a dos demandas de accionistas (Drulias v. Babiak, Johnson v. WBA) y 11 cartas de demanda que alegan omisiones materiales en el poder original. Aunque WBA considera que las reclamaciones carecen de fundamento, la compañía está añadiendo información narrativa y cuantitativa detallada para zanjar los desafíos de divulgación y evitar posibles medidas cautelares antes de la reunión especial de accionistas del 11 de julio de 2025.
Adiciones clave incluyen: (1) ampliación del contexto sobre las negociaciones con Sycamore, términos de confidencialidad y deliberaciones del consejo; (2) descripciones más completas de los memorandos de divulgación de relaciones de Centerview y Morgan Stanley; (3) análisis de valoración detallados—comparables de empresas públicas, transacciones precedentes, flujo de caja descontado (DCF) y análisis de primas pagadas—con múltiplos explícitos, tasas de descuento y ajustes de pasivos; y (4) actualización de la información financiera prospectiva (Proyecciones de febrero, Pronósticos VMD, iteraciones previas de proyecciones).
Aspectos destacados de la valoración: el enfoque de Centerview basado en empresas públicas seleccionadas implica un valor patrimonial de $4.60 a $12.70 por acción, el análisis de transacciones precedentes de $6.90 a $15.20, y el DCF de $10.80 a $19.10. Los múltiplos P/E estimados por Morgan Stanley para 2025 arrojan un valor de $7.95 a $12.25, mientras que su análisis de primas pagadas sugiere un precio implícito de $10.60 a $12.80. Estos rangos abarcan la consideración de la fusión de $12.64–$13.36 divulgada en el poder.
Estado de las demandas: Los demandantes buscan detener la votación hasta que se proporcione información adicional y solicitan honorarios legales. WBA informa que pueden llegar más demandas o cartas de demanda, pero no necesariamente serán reportadas sin nuevas alegaciones.
Perspectivas financieras (Proyecciones de febrero): ingresos para FY2025 de $154.6 mil millones, EBITDA ajustado de $3.71 mil millones, flujo de caja libre sin apalancamiento de $1.99 mil millones. Se proyecta que el EBITDA ajustado crezca a $4.70 mil millones para FY2029. Los principales factores negativos incluyen pagos por opioides, obligaciones de alquiler oscuro y costos de cierre de tiendas.
Contexto estratégico: El consejo continúa recomendando la transacción con Sycamore y señala un interés limitado de patrocinadores o estratégicos alternativos. Se mantiene una fase de “go-shop” como parte de la estructura del acuerdo. WBA reitera que no admite la materialidad de las nuevas divulgaciones.
Walgreens Boots Alliance, Inc. (WBA)는 Sycamore Partners(“Blazing Star Parent”) 계열사와의 진행 중인 합병에 관한 최종 위임장 설명서를 자발적으로 보완하기 위해 Form 8-K를 제출했습니다. 이번 보완은 두 건의 주주 소송(Drulias v. Babiak, Johnson v. WBA)과 11건의 요구서에 대응한 것으로, 원래 위임장에 중대한 누락이 있다고 주장합니다. WBA는 이러한 주장이 근거 없다고 보지만, 2025년 7월 11일 특별 주주총회 이전에 공개 문제를 해소하고 잠재적 금지명령을 피하기 위해 상세한 서술 및 정량 정보를 추가하고 있습니다.
주요 추가 내용은 다음과 같습니다: (1) Sycamore와의 협상 배경, 비밀 유지 조건 및 이사회 심의 확대; (2) Centerview와 Morgan Stanley의 관계 공개 메모 완전한 설명; (3) 공개 기업 비교, 선례 거래, 할인 현금 흐름(DCF) 및 프리미엄 지급 분석을 포함한 세부 평가 작업—명확한 배수, 할인율 및 부채 조정 포함; (4) 최신 전망 재무 정보(2월 예측, VMD 전망, 이전 예측 버전).
평가 하이라이트: Centerview의 선정된 공개 기업 접근법은 주당 $4.60–$12.70의 자본 가치를 시사하며, 선례 거래 분석은 $6.90–$15.20, DCF는 $10.80–$19.10입니다. Morgan Stanley의 2025년 예상 주가수익비율(P/E) 비교는 $7.95–$12.25를 산출하며, 프리미엄 지급 분석은 $10.60–$12.80의 암시적 가격을 제시합니다. 이 범위들은 위임장에 공개된 합병 대가 $12.64–$13.36를 포함합니다.
소송 현황: 원고들은 추가 정보 제공 전 투표 중단을 요구하며 변호사 비용도 청구하고 있습니다. WBA는 추가 소송이나 요구서가 도착할 수 있으나 새로운 주장 없이는 반드시 보고하지는 않을 것이라고 밝혔습니다.
재무 전망 (2월 예측): 2025 회계연도 매출 $1546억, 조정 EBITDA $37.1억, 무차입 자유현금흐름 $19.9억. 조정 EBITDA는 2029 회계연도까지 $47.0억으로 성장할 것으로 예상됩니다. 주요 부담 요소는 오피오이드 지급, 암대여 의무, 매장 폐쇄 비용입니다.
전략적 맥락: 이사회는 Sycamore 거래를 계속 추천하며 대체 스폰서나 전략적 투자자들의 관심이 제한적임을 언급합니다. "고샵(go-shop)" 조항은 합의된 거래 구조의 일부로 유지됩니다. WBA는 새로운 공개 내용의 중요성을 인정하지 않음을 재확인합니다.
Walgreens Boots Alliance, Inc. (WBA) a déposé un formulaire 8-K pour compléter volontairement la déclaration définitive de procuration concernant sa fusion en cours avec des filiales de Sycamore Partners (« Blazing Star Parent »). Ces compléments répondent à deux poursuites d’actionnaires (Drulias c. Babiak, Johnson c. WBA) et à 11 lettres de demande alléguant des omissions matérielles dans la procuration originale. Bien que WBA considère ces allégations comme infondées, la société ajoute des informations narratives et quantitatives détaillées afin de résoudre les contestations relatives aux divulgations et d’éviter d’éventuelles injonctions avant l’assemblée générale extraordinaire des actionnaires du 11 juillet 2025.
Ajouts clés : (1) contexte élargi sur les négociations avec Sycamore, les termes de confidentialité et les délibérations du conseil d’administration ; (2) descriptions plus complètes des mémorandums de divulgation des relations de Centerview et Morgan Stanley ; (3) analyses d’évaluation détaillées—comparables d’entreprises cotées, transactions antérieures, flux de trésorerie actualisés (DCF) et analyses des primes payées—avec multiples explicites, taux d’actualisation et ajustements de passifs ; (4) informations financières prospectives actualisées (prévisions de février, prévisions VMD, itérations précédentes).
Points forts de l’évaluation : l’approche de Centerview basée sur des entreprises cotées sélectionnées implique une valeur des capitaux propres comprise entre 4,60 $ et 12,70 $ par action, l’analyse des transactions antérieures entre 6,90 $ et 15,20 $, et le DCF entre 10,80 $ et 19,10 $. Les multiples P/E estimés par Morgan Stanley pour 2025 donnent une fourchette de 7,95 $ à 12,25 $, tandis que son analyse des primes payées suggère un prix implicite de 10,60 $ à 12,80 $. Ces fourchettes encadrent la contrepartie de fusion de 12,64 $–13,36 $ divulguée dans la procuration.
Situation des poursuites : Les plaignants demandent de suspendre le vote jusqu’à la fourniture d’informations supplémentaires et réclament les frais d’avocat. WBA indique que d’autres poursuites ou lettres de demande pourraient arriver, mais ne seront pas nécessairement signalées en l’absence de nouvelles allégations.
Perspectives financières (prévisions de février) : chiffre d’affaires pour l’exercice 2025 de 154,6 milliards de $, EBITDA ajusté de 3,71 milliards de $, flux de trésorerie disponible non levier de 1,99 milliard de $. L’EBITDA ajusté devrait atteindre 4,70 milliards de $ d’ici l’exercice 2029. Les principaux freins comprennent les paiements liés aux opioïdes, les obligations de loyers cachés et les coûts de fermeture de magasins.
Contexte stratégique : Le conseil continue de recommander la transaction avec Sycamore et note un intérêt limité de la part d’autres sponsors ou acteurs stratégiques. Une période de « go-shop » reste incluse dans la structure de l’accord. WBA réitère qu’elle ne reconnaît pas la matérialité des nouvelles divulgations.
Walgreens Boots Alliance, Inc. (WBA) hat ein Formular 8-K eingereicht, um freiwillig die endgültige Vollmachtsmitteilung für die bevorstehende Fusion mit Tochtergesellschaften von Sycamore Partners („Blazing Star Parent“) zu ergänzen. Die Ergänzungen reagieren auf zwei Aktionärsklagen (Drulias gegen Babiak, Johnson gegen WBA) und 11 Aufforderungsschreiben, die wesentliche Auslassungen in der ursprünglichen Vollmacht behaupten. Obwohl WBA die Ansprüche für unbegründet hält, fügt das Unternehmen detaillierte narrative und quantitative Informationen hinzu, um Offenlegungsstreitigkeiten auszuräumen und mögliche einstweilige Verfügungen vor der außerordentlichen Hauptversammlung am 11. Juli 2025 zu vermeiden.
Wesentliche Ergänzungen umfassen: (1) erweiterte Hintergrundinformationen zu Verhandlungen mit Sycamore, Vertraulichkeitsbedingungen und Vorstandsdiskussionen; (2) ausführlichere Beschreibungen der Beziehungsoffenlegungsmemoranden von Centerview und Morgan Stanley; (3) detaillierte Bewertungsanalysen—vergleichbare börsennotierte Unternehmen, frühere Transaktionen, Discounted Cash Flow (DCF) und bezahlte Prämien—mit expliziten Multiplikatoren, Diskontierungssätzen und Haftungsanpassungen; sowie (4) aktualisierte vorausschauende Finanzinformationen (Februar-Prognosen, VMD-Forecasts, frühere Prognoseversionen).
Bewertungs-Highlights: Der von Centerview gewählte Ansatz mit vergleichbaren börsennotierten Unternehmen impliziert einen Eigenkapitalwert von $4,60–$12,70 pro Aktie, die Analyse früherer Transaktionen $6,90–$15,20 und der DCF $10,80–$19,10. Die von Morgan Stanley für das Jahr 2025 geschätzten KGV-Vergleiche ergeben $7,95–$12,25, während die Analyse der gezahlten Prämien einen impliziten Preis von $10,60–$12,80 nahelegt. Diese Spannen umfassen die in der Vollmacht angegebenen Fusionsgegenleistungen von $12,64–$13,36.
Rechtslage: Die Kläger verlangen eine Aussetzung der Abstimmung bis zur Bereitstellung zusätzlicher Informationen und fordern Anwaltskosten. WBA gibt an, dass weitere Klagen oder Aufforderungsschreiben eintreffen können, diese jedoch ohne neue Vorwürfe nicht unbedingt gemeldet werden.
Finanzielle Prognose (Februar-Prognosen): Umsatz für das Geschäftsjahr 2025 $154,6 Mrd., bereinigtes EBITDA $3,71 Mrd., unbelasteter Free Cashflow $1,99 Mrd.. Das bereinigte EBITDA soll bis zum Geschäftsjahr 2029 auf $4,70 Mrd. wachsen. Wesentliche Belastungen sind Opioid-Zahlungen, verdeckte Mietverpflichtungen und Kosten für Filialschließungen.
Strategischer Kontext: Der Vorstand empfiehlt weiterhin die Sycamore-Transaktion und weist auf begrenztes Interesse alternativer Sponsoren oder strategischer Investoren hin. Eine „Go-Shop“-Phase bleibt Teil der vereinbarten Struktur. WBA betont, dass keine Anerkennung der Wesentlichkeit der neuen Offenlegungen erfolgt.
JPMorgan Chase Financial Company LLC 3yr BAC Contingent Income Auto - Callable Securities Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement Nos. 333 - 270004 and 333 - 270004 - 01 Dated June 18, 2025 This document provides a summary of the terms of the securities. Investors must carefully review the accompanying preliminary pricing supplement referenced below, product supplement, prospectus supplement and prospectus and the “Risk Considerations” on the following page, prior to making an investment decision. SUMMARY TERMS JPMorgan Chase Financial Company LLC ("JPMorgan Financial") Issuer: JPMorgan Chase & Co. Guarantor: Common stock of Bank of America Corporation (Bloomberg ticker: BAC UN Equity) Underlying stock: Early redemption: If, on any determination date (other than the final determination date), the closing price of the underlying stock is greater than or equal to the initial stock price, the securities will be automatically redeemed for an early redemption payment on the first contingent payment date immediately following the related determination date. No further payments will be made on the securities once they have been redeemed. The securities will not be redeemed early on any contingent payment date if the closing price of the underlying stock is below the initial stock price on the related determination date. Early redemption payment: The early redemption payment will be an amount equal to (i) the stated principal amount plus (ii) the contingent quarterly payment with respect to the related determination date. Contingent quarterly Ɣ If, on any determination date, the closing price of the underlying stock is greater payment: than or equal to the downside threshold level, we will pay a contingent quarterly payment of at least $25.25 (at least 2.525% of the stated principal amount) per security on the related contingent payment date. The actual contingent quarterly payment will be provided in the pricing supplement. ● If, on any determination date, the closing price of the underlying stock is less than the downside threshold level, no contingent quarterly payment will be made with respect to that determination date. It is possible that the closing price of the underlying stock will be below the downside threshold level on most or all of the determination dates so that you will receive few or no contingent quarterly payments. Determination dates † : September 29, 2025, December 29, 2025, March 27, 2026, June 29, 2026, September 28, 2026, December 28, 2026, March 29, 2027, June 28, 2027, September 27, 2027, December 27, 2027, March 27, 2028 and June 27, 2028 Contingent payment dates † : October 2, 2025, January 2, 2026, April 1, 2026, July 2, 2026, October 1, 2026, December 31, 2026, April 1, 2027, July 1, 2027, September 30, 2027, December 30, 2027, March 30, 2028 and the maturity date Payment at maturity: Ɣ If the final stock price is greater than or equal to the downside threshold level: ● If the final stock price is less than the downside threshold level: (i) the stated principal amount plus (ii) the contingent quarterly payment with respect to the final determination date (i) the stated principal amount times (ii) the stock performance factor. This cash payment will be less than 70% of the stated principal amount of the securities and could be zero. Downside threshold level: 70% of the initial stock price Initial stock price: The closing price of the underlying stock on the pricing date Final stock price: The closing price of the underlying stock on the final determination date Stock adjustment factor: The stock adjustment factor is referenced in determining the closing price of the underlying stock and is set initially at 1.0 on the pricing date. The stock adjustment factor is subject to adjustment in the event of certain corporate events affecting the underlying stock. Stock performance final stock price / initial stock price factor: Stated principal $1,000 per security amount: Issue price: $1,000 per security Pricing date: Expected to be June 27, 2025 Original issue date 3 business days after the pricing date (settlement date): Maturity date † : June 30, 2028 CUSIP / ISIN: 48136ES97 / US48136ES976 Preliminary pricing supplement: http://sp.jpmorgan.com/document/cusip/48136ES97/doctype/Product_Termsheet/ document.pdf †Subject to postponement The estimated value of the securities on the pricing date will be provided in the pricing supplement and will not be less than $ 940 . 00 per $ 1 , 000 stated principal amount security . For information about the estimated value of the securities, which likely will be lower than the price you paid for the securities, please see the hyperlink above . Any payment on the securities is subject to the credit risk of JPMorgan Financial as issuer of the securities, and the credit risk of JPMorgan Chase & Co., as guarantor of the securities. Hypothetical Payout at Maturity (if the securities have not previously been redeemed) Change in Underlying Stock Payment at Maturity (excluding any coupon payable at maturity) 50.00% $1,000.000 40.00% $1,000.000 30.00% $1,000.000 20.00% $1,000.000 10.00% $1,000.000 5.00% $1,000.000 0.00% $1,000.000 - 10.00% $1,000.000 - 20.00% $1,000.000 - 30.00% $1,000.000 - 30.01% $699.900 - 40.00% $600.000 - 50.00% $500.000 - 60.00% $400.000 - 80.00% $200.000 - 100.00% $0.000
JPMorgan Chase Financial Company LLC 3yr BAC Contingent Income Auto - Callable Securities Underlying Stock For more information about the underlying stock, including historical performance information, see the accompanying preliminary pricing supplement. Risk Considerations The risks identified below are not exhaustive. Please see “Risk Factors” in the accompanying prospectus supplement, product supplement and preliminary pricing supplement for additional information. Risks Relating to the Securities Generally ■ The securities do not guarantee the return of any principal and your investment in the securities may result in a loss. ■ You will not receive any contingent quarterly payment for any quarterly period if the closing price of the underlying stock on the relevant determination date is less than the downside threshold level. ■ The contingent quarterly payment is based solely on the closing prices of the underlying stock on the specified determination dates. ■ The securities are subject to the credit risks of JPMorgan Financial and JPMorgan Chase & Co., and any actual or anticipated changes to our or JPMorgan Chase & Co.’s credit ratings or credit spreads may adversely affect the market value of the securities. ■ As a finance subsidiary, JPMorgan Financial has no independent operations and has limited assets. ■ Investors will not participate in any appreciation of the underlying stock. ■ Early redemption risk. ■ Secondary trading may be limited. ■ The final terms and estimated valuation of the securities will be provided in the pricing supplement. ■ The U.S. federal income tax consequences of an investment in the securities are uncertain. Risks Relating to Conflicts of Interest ■ Economic interests of the issuer, the guarantor, the calculation agent, the agent of the offering of the securities and other affiliates of the issuer may be different from those of investors. ■ Hedging and trading activities by the issuer and its affiliates could potentially affect the value of the securities. Risks Relating to the Estimated Value and Secondary Market Prices of the Securities ■ The estimated value of the securities will be lower than the original issue price (price to public) of the securities. ■ The estimated value of the securities does not represent future values of the securities and may differ from others’ estimates. ■ The estimated value of the securities is derived by reference to an internal funding rate. ■ The value of the securities as published by J.P. Morgan Securities LLC (and which may be reflected on customer account statements) may be higher than the then - current estimated value of the securities for a limited time period. ■ Secondary market prices of the securities will likely be lower than the original issue price of the securities. ■ Secondary market prices of the securities will be impacted by many economic and market factors. Risks Relating to the Underlying Stock ■ Investing in the securities is not equivalent to investing in the underlying stock. ■ No affiliation with Bank of America Corporation. ■ We may engage in business with or involving Bank of America Corporation without regard to your interests. ■ The anti - dilution protection for the underlying stock is limited and may be discretionary. ■ Governmental legislative and regulatory actions, including sanctions, could adversely affect your investment in the securities. Tax Considerations You should review carefully the discussion in the accompanying preliminary pricing supplement under “Additional Information about the Securities — Tax considerations” concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser. SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a prospectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participating in the this offering will arrange to send you the prospectus and each prospectus supplement as well as any product supplement and preliminary pricing supplement if you so request by calling toll - free 1 - 866 - 535 - 9248.
FAQ
When is the Walgreens Boots Alliance (WBA) shareholder vote on the Sycamore merger?
What lawsuits have been filed against WBA regarding the merger?
What are Centerview’s updated discounted cash-flow (DCF) valuation ranges for WBA?
How does Morgan Stanley’s public trading comparables analysis value WBA shares?
What key liabilities were deducted in the valuation analyses?
What is WBA’s projected Adjusted EBITDA for fiscal 2025 under the February Projections?
Does the 8-K change the terms of the Sycamore merger?
